Evangeline S Q Ho1, Sarah A Barrett1, Laura M Mullaney1. 1. a Applied Radiation Therapy Trinity, Discipline of Radiation Therapy, School of Medicine , Trinity College Dublin , Dublin , Ireland.
Abstract
BACKGROUND: Craniospinal irradiation (CSI) is the standard radiation therapy treatment for medulloblastoma. Conventional CSI photon therapy (Photon-CSI) delivers significant dose to surrounding normal tissue (NT). Research into pediatric CSI with proton therapy (Proton-CSI) has increased, with the aim of exploiting the potential to reduce NT dose and associated post-treatment complications. This review aims to compare treatment outcomes of pediatric medulloblastoma patients between Proton- and Photon-CSI treatments. MATERIAL AND METHODS: A search and review of studies published between 1990 and 2016 comparing pediatric (2-18 years) medulloblastoma Proton- and Photon-CSI in three aspects - normal organ sparing and target coverage; normal organ dysfunction and second malignancy risks - was completed. RESULTS: Fifteen studies were selected for review and the results were directly compared. Proton-CSI reported improved out-of-field organ sparing while target coverage improvements were inconsistent. Normal organ dysfunction risks were predicted to be lower following Proton-CSI. Secondary malignancy risks (SMRs) were generally lower with Proton-CSI based on several different risk models. CONCLUSIONS: Proton-CSI conferred better treatment outcomes than Photon-CSI for pediatric medulloblastoma patients. This review serves to compare the current literature in the absence of long-term data from prospective studies.
BACKGROUND: Craniospinal irradiation (CSI) is the standard radiation therapy treatment for medulloblastoma. Conventional CSI photon therapy (Photon-CSI) delivers significant dose to surrounding normal tissue (NT). Research into pediatric CSI with proton therapy (Proton-CSI) has increased, with the aim of exploiting the potential to reduce NT dose and associated post-treatment complications. This review aims to compare treatment outcomes of pediatric medulloblastomapatients between Proton- and Photon-CSI treatments. MATERIAL AND METHODS: A search and review of studies published between 1990 and 2016 comparing pediatric (2-18 years) medulloblastoma Proton- and Photon-CSI in three aspects - normal organ sparing and target coverage; normal organ dysfunction and second malignancy risks - was completed. RESULTS: Fifteen studies were selected for review and the results were directly compared. Proton-CSI reported improved out-of-field organ sparing while target coverage improvements were inconsistent. Normal organ dysfunction risks were predicted to be lower following Proton-CSI. Secondary malignancy risks (SMRs) were generally lower with Proton-CSI based on several different risk models. CONCLUSIONS: Proton-CSI conferred better treatment outcomes than Photon-CSI for pediatric medulloblastomapatients. This review serves to compare the current literature in the absence of long-term data from prospective studies.
Authors: Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Eric Bouffet; Murali Chintagumpala; Donald Mabbott Journal: J Clin Oncol Date: 2020-05-06 Impact factor: 44.544
Authors: Vidya Puthenpura; Nicholas J DeNunzio; Xue Zeng; Drosoula Giantsoudi; Mariam Aboian; David Ebb; Kristopher T Kahle; Torunn I Yock; Asher M Marks Journal: Int J Part Ther Date: 2021-07-29
Authors: Enrico Franceschi; Caterina Giannini; Julia Furtner; Kristian W Pajtler; Sofia Asioli; Raphael Guzman; Clemens Seidel; Lidia Gatto; Peter Hau Journal: Cancers (Basel) Date: 2022-07-29 Impact factor: 6.575
Authors: Tien T Tang; Janice A Zawaski; Shelli Kesler; Christine A Beamish; Taeko Inoue; Emma C Perez; Lawrence Bronk; Falk Poenisch; Tina M Briere; Omaima M Sabek; David R Grosshans; M Waleed Gaber Journal: Int J Radiat Oncol Biol Phys Date: 2021-09-09 Impact factor: 7.038